中国实用妇科与产科杂志2024，Vol.40Issue(11)：1078-1082,5.DOI:10.19538/j.fk2024110106
卵巢癌免疫检查点抑制剂应用的现状与挑战
Immune checkpoint blockades for ovarian can-cer:current status and challenges
摘要
Abstract
Immune checkpoint blockades(ICBs)have achieved breakthrough in the treatment of multiple solid tumors.However,in the treatment of ovarian cancer,mainly high grade serous tubo-ovarian cancer(HGSC),neither single agent of ICBs nor ICB-based combination therapies have shown good results in clinical researches.The tumor immune microenviron-ment of ovarian cancer is highly complex and heter-ogenous,with low PD-L1 expression,low tumor mutation burden,different phenotypes of lymphocytes infiltration in tumors,and presence of multiple im-munosuppressive cells.We still need well-designed clinical trials considering the patients'genomic and immune phenotypes to improve the accuracy and ef-fectiveness of treatment.关键词
卵巢癌/免疫检查点抑制剂/肿瘤免疫微环境Key words
ovarian cancer/immune checkpoint blockade/tumor immune microenvironment分类
医药卫生引用本文复制引用
陈雨莲,臧荣余..卵巢癌免疫检查点抑制剂应用的现状与挑战[J].中国实用妇科与产科杂志,2024,40(11):1078-1082,5.基金项目
国家自然科学基金面上项目(82473027 （）
82273388) （）
上海市科学技术委员会医学创新研究专项(22Y21900300) （22Y21900300）
